LEGEND BIOTECH CORP-ADR (LEGN) Fundamental Analysis & Valuation

NASDAQ:LEGN • US52490G1022

20.085 USD
+0.53 (+2.68%)
Last: Mar 11, 2026, 11:43 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This LEGN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

Taking everything into account, LEGN scores 3 out of 10 in our fundamental rating. LEGN was compared to 519 industry peers in the Biotechnology industry. The financial health of LEGN is average, but there are quite some concerns on its profitability. LEGN does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

2

1. LEGN Profitability Analysis

1.1 Basic Checks

  • In the past year LEGN has reported negative net income.
  • In the past year LEGN has reported a negative cash flow from operations.
  • LEGN had negative earnings in each of the past 5 years.
  • In the past 5 years LEGN always reported negative operating cash flow.
LEGN Yearly Net Income VS EBIT VS OCF VS FCFLEGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M -400M

1.2 Ratios

  • With an excellent Return On Assets value of -14.01%, LEGN belongs to the best of the industry, outperforming 80.54% of the companies in the same industry.
  • The Return On Equity of LEGN (-23.73%) is better than 79.58% of its industry peers.
Industry RankSector Rank
ROA -14.01%
ROE -23.73%
ROIC N/A
ROA(3y)-24.06%
ROA(5y)-29.02%
ROE(3y)-39.46%
ROE(5y)-43.13%
ROIC(3y)N/A
ROIC(5y)N/A
LEGN Yearly ROA, ROE, ROICLEGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

1.3 Margins

  • LEGN has a better Gross Margin (60.55%) than 78.03% of its industry peers.
  • The Profit Margin and Operating Margin are not available for LEGN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 60.55%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LEGN Yearly Profit, Operating, Gross MarginsLEGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. LEGN Health Analysis

2.1 Basic Checks

  • LEGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • There is no outstanding debt for LEGN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
LEGN Yearly Shares OutstandingLEGN Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
LEGN Yearly Total Debt VS Total AssetsLEGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

  • An Altman-Z score of 4.62 indicates that LEGN is not in any danger for bankruptcy at the moment.
  • LEGN's Altman-Z score of 4.62 is fine compared to the rest of the industry. LEGN outperforms 70.71% of its industry peers.
  • A Debt/Equity ratio of 0.26 indicates that LEGN is not too dependend on debt financing.
  • LEGN's Debt to Equity ratio of 0.26 is on the low side compared to the rest of the industry. LEGN is outperformed by 66.09% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF N/A
Altman-Z 4.62
ROIC/WACCN/A
WACC8.24%
LEGN Yearly LT Debt VS Equity VS FCFLEGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

  • LEGN has a Current Ratio of 2.86. This indicates that LEGN is financially healthy and has no problem in meeting its short term obligations.
  • LEGN has a Current ratio of 2.86. This is in the lower half of the industry: LEGN underperforms 65.51% of its industry peers.
  • A Quick Ratio of 2.80 indicates that LEGN has no problem at all paying its short term obligations.
  • LEGN has a worse Quick ratio (2.80) than 64.35% of its industry peers.
Industry RankSector Rank
Current Ratio 2.86
Quick Ratio 2.8
LEGN Yearly Current Assets VS Current LiabilitesLEGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. LEGN Growth Analysis

3.1 Past

  • The earnings per share for LEGN have decreased strongly by -60.00% in the last year.
EPS 1Y (TTM)-60%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-153.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%64.22%

3.2 Future

  • Based on estimates for the next years, LEGN will show a very strong growth in Earnings Per Share. The EPS will grow by 33.29% on average per year.
  • Based on estimates for the next years, LEGN will show a very strong growth in Revenue. The Revenue will grow by 20.65% on average per year.
EPS Next Y122.14%
EPS Next 2Y69.08%
EPS Next 3Y44.02%
EPS Next 5Y33.29%
Revenue Next Year43.2%
Revenue Next 2Y35.79%
Revenue Next 3Y35.33%
Revenue Next 5Y20.65%

3.3 Evolution

LEGN Yearly Revenue VS EstimatesLEGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 1B 2B 3B
LEGN Yearly EPS VS EstimatesLEGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2

More info and screens

Find the best growth stocksShow best growing peers

3

4. LEGN Valuation Analysis

4.1 Price/Earnings Ratio

  • LEGN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • LEGN is valuated quite expensively with a Price/Forward Earnings ratio of 59.68.
  • 90.17% of the companies in the same industry are more expensive than LEGN, based on the Price/Forward Earnings ratio.
  • LEGN is valuated expensively when we compare the Price/Forward Earnings ratio to 24.39, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 59.68
LEGN Price Earnings VS Forward Price EarningsLEGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LEGN Per share dataLEGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

  • LEGN's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as LEGN's earnings are expected to grow with 44.02% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y69.08%
EPS Next 3Y44.02%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. LEGN Dividend Analysis

5.1 Amount

  • No dividends for LEGN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

LEGN Fundamentals: All Metrics, Ratios and Statistics

LEGEND BIOTECH CORP-ADR

NASDAQ:LEGN (3/11/2026, 11:43:47 AM)

20.085

+0.53 (+2.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-10
Earnings (Next)N/A
Inst Owners50.35%
Inst Owner Change4.15%
Ins Owners0.08%
Ins Owner ChangeN/A
Market Cap3.68B
Revenue(TTM)N/A
Net Income(TTM)-239.99M
Analysts82.4
Price Target65.8 (227.61%)
Short Float %24.16%
Short Ratio8.63
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-260.82%
Min EPS beat(2)-366.2%
Max EPS beat(2)-155.43%
EPS beat(4)1
Avg EPS beat(4)-127.99%
Min EPS beat(4)-366.2%
Max EPS beat(4)147.06%
EPS beat(8)2
Avg EPS beat(8)-64.68%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)3.59%
Min Revenue beat(2)-2.02%
Max Revenue beat(2)9.2%
Revenue beat(4)2
Avg Revenue beat(4)2.04%
Min Revenue beat(4)-2.02%
Max Revenue beat(4)9.2%
Revenue beat(8)4
Avg Revenue beat(8)1.55%
Revenue beat(12)6
Avg Revenue beat(12)20.38%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.31%
PT rev (3m)-12.21%
EPS NQ rev (1m)-86.26%
EPS NQ rev (3m)-64.91%
EPS NY rev (1m)-5.8%
EPS NY rev (3m)-5.74%
Revenue NQ rev (1m)-0.3%
Revenue NQ rev (3m)-3.63%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.76%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 59.68
P/S 4.05
P/FCF N/A
P/OCF N/A
P/B 3.64
P/tB 3.64
EV/EBITDA N/A
EPS(TTM)-1.52
EYN/A
EPS(NY)0.34
Fwd EY1.68%
FCF(TTM)-1.03
FCFYN/A
OCF(TTM)-0.93
OCFYN/A
SpS4.95
BVpS5.51
TBVpS5.51
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -14.01%
ROE -23.73%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 60.55%
FCFM N/A
ROA(3y)-24.06%
ROA(5y)-29.02%
ROE(3y)-39.46%
ROE(5y)-43.13%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.53
Health
Industry RankSector Rank
Debt/Equity 0.26
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 78.25%
Cap/Sales 2.01%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.86
Quick Ratio 2.8
Altman-Z 4.62
F-Score4
WACC8.24%
ROIC/WACCN/A
Cap/Depr(3y)97.56%
Cap/Depr(5y)226.91%
Cap/Sales(3y)9.76%
Cap/Sales(5y)32.83%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-60%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-153.33%
EPS Next Y122.14%
EPS Next 2Y69.08%
EPS Next 3Y44.02%
EPS Next 5Y33.29%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%64.22%
Revenue Next Year43.2%
Revenue Next 2Y35.79%
Revenue Next 3Y35.33%
Revenue Next 5Y20.65%
EBIT growth 1Y45.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year48.94%
EBIT Next 3Y51.94%
EBIT Next 5Y37.37%
FCF growth 1Y61.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y63.38%
OCF growth 3YN/A
OCF growth 5YN/A

LEGEND BIOTECH CORP-ADR / LEGN FAQ

What is the ChartMill fundamental rating of LEGEND BIOTECH CORP-ADR (LEGN) stock?

ChartMill assigns a fundamental rating of 4 / 10 to LEGN.


Can you provide the valuation status for LEGEND BIOTECH CORP-ADR?

ChartMill assigns a valuation rating of 2 / 10 to LEGEND BIOTECH CORP-ADR (LEGN). This can be considered as Overvalued.


Can you provide the profitability details for LEGEND BIOTECH CORP-ADR?

LEGEND BIOTECH CORP-ADR (LEGN) has a profitability rating of 2 / 10.


What is the financial health of LEGEND BIOTECH CORP-ADR (LEGN) stock?

The financial health rating of LEGEND BIOTECH CORP-ADR (LEGN) is 4 / 10.